Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1099/0022-1317-22-2-207 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enterovirus Antibodies: Friends and Foes.
Rev Med Virol
November 2024
Laboratoire de Virologie URL3610, Univ. Lille et CHU Lille, Lille, France.
Enteroviruses (EV) initiate replication by binding to their cellular receptors, leading to the uncoating and release of the viral genome into the cytosol of the host cell. Neutralising antibodies (NAbs) binding to epitopes on enteroviral capsid proteins can inhibit this infectious process through several mechanisms of neutralisation in vitro. Fc-mediated antibody effector functions such as antibody-dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis have also been described for some EV.
View Article and Find Full Text PDFRecent Progress of Antisense Oligonucleotide Therapy for -Mutated Amyotrophic Lateral Sclerosis: Focus on Tofersen.
Genes (Basel)
October 2024
Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2H7, Canada.
Amyotrophic lateral sclerosis (ALS) is a refractory neurodegenerative disease characterized by the degeneration and loss of motor neurons, typically resulting in death within five years of onset. There have been few effective treatments, making the development of robust therapies an urgent challenge. Genetic mutations have been identified as contributors to ALS, with mutations in (), which neutralizes the harmful reactive oxygen species superoxide, accounting for approximately 2% of all ALS cases.
View Article and Find Full Text PDFRandomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma.
Lung Cancer
September 2024
National Cancer Institute, 9609 Medical Center Dr., Rockville, MD 20850, USA. Electronic address:
Purpose: The mesothelin-targeting antibody-drug conjugate anetumab ravtansine was evaluated in combination with the programmed cell death-1 (PD-1) inhibitor pembrolizumab based on the common expression of mesothelin and reports of activity in mesothelioma.
Patients And Methods: A phase 1 safety run-in of the combination of anetumab ravtansine (6.5 mg/kg iv q3weeks) and pembrolizumab (200 mg, IV q3weeks) was conducted, followed by a phase 2 randomization to the combination or pembrolizumab alone at medical centers across the United States and Canada in the National Cancer Institute's Experimental Therapeutics Clinical Trials Network.
Friend or foe: classifying collaborative interactions using fNIRS.
Front Neuroergon
October 2023
Psychology and Neuroscience, University of Colorado, Boulder, CO, United States.
To succeed, effective teams depend on both cooperative and competitive interactions between individual teammates. Depending on the context, cooperation and competition can amplify or neutralize a team's problem solving ability. Therefore, to assess successful collaborative problem solving, it is first crucial to distinguish competitive from cooperative interactions.
View Article and Find Full Text PDFC1 esterase inhibitor-mediated immunosuppression in COVID-19: Friend or foe?
Clin Immunol Commun
December 2022
Department of Trauma Research, Swedish Medical Center, 501 E. Hampden, Englewood, CO 80113, USA.
Article Synopsis
- SARS-CoV-2 causes a range of COVID-19 disease severities, influenced by immune responses that are affected by variants like Omicron.
- * The protein C1 esterase inhibitor (C1-INH), which regulates the immune system, is found at higher levels in severe COVID-19 cases and may paradoxically worsen the disease.
- * This review discusses C1-INH’s role in immune response and explores current clinical trials testing exogenous C1-INH treatment for COVID-19.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!